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Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease
The Recovery Trial
Objectives The goal of this study was to assess the offset of the antiplatelet effects of prasugrel and clopidogrel.
Background Guidelines recommend discontinuing clopidogrel at least 5 days and prasugrel at least 7 days before surgery.
The pharmacodynamic basis for these recommendations is limited.
Methods Aspirin-treated patients with coronary artery disease were randomly assigned to either prasugrel 10 mg or clopi-
dogrel 75 mg daily for 7 days. Platelet reactivity was measured before study drug administration and for up to
12 days during washout. The primary endpoint was the cumulative proportion of patients returning to baseline
reactivity after study drug discontinuation.
Results A total of 56 patients were randomized; 54 were eligible for analysis. Platelet reactivity was lower 24 h after the
last dose of prasugrel compared with clopidogrel. After prasugrel,75% of patients returned to baseline reactivity by
washout day 7 compared with day 5 after clopidogrel. Recovery time was dependent on the level of platelet reactivity be-
fore study drug exposure and the initial degree of platelet inhibition after study drug discontinuation but not on treatment
assignment.
Conclusions Recovery time after thienopyridine discontinuation depends on the magnitude of on-treatment platelet inhibi-
tion, resulting, on average, in a more delayed recovery with prasugrel compared with clopidogrel. The offset of
prasugrel was consistent with current guidelines regarding the recommended waiting period for surgery after
discontinuation. (Prasugrel/Clopidogrel Maintenance Dose Washout Study; NCT01014624) (J Am Coll Cardiol
2012;59:2338–43) © 2012 by the American College of Cardiology Foundationc
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wThienopyridines are prodrugs that require biotransformation
into an active metabolite that irreversibly antagonizes the
P2Y12 receptor for the platelet’s lifespan. A prasugrel 60-mg
oading dose and 10-mg daily maintenance dose (MD) provide
reater and more consistent levels of platelet inhibition than
lopidogrel due to more efficient active metabolite generation
1,2). Clopidogrel use before cardiac surgery increases bleeding
3,4). In the 437 patients who underwent coronary artery
ypass graft (CABG) in the TRITON–TIMI 38 (Trial to
ssess Improvement in Therapeutic Outcomes by Optimizing
latelet Inhibition with Prasugrel–Thrombolysis In Myocar-
ial Infarction 38) trial, more bleeding occurred with prasugrel
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012, accepted February 22, 2012.ompared with clopidogrel up to 1 week after discontinuation
5). Based on these clinical observations, the American College
f Cardiology/American Heart Association guidelines recom-
end empirical discontinuation of clopidogrel for at least 5
ays and prasugrel for at least 7 days before planned CABG,
nless the net benefit of the thienopyridine outweighs the
otential risks of excess bleeding (6). However, the dynamics of
latelet functional recovery after prasugrel cessation have not
een specifically assessed. Therefore, we performed this study
o examine the relationship between the timing of drug
iscontinuation and the recovery of platelet function after
rasugrel compared with clopidogrel therapy.
ethods
tudy design. This trial was a randomized, double-blinded
tudy conducted at 4 sites in the United States. The study was
pproved by the institutional review boards at all sites and was
onducted in accord with the provisions of the Declaration of
elsinki. All subjects provided written informed consent.
tudy population. Subjects were eligible to be enrolled if they
ere75 years of age, had stable coronary artery disease (CAD),
nd were receiving aspirin. Detailed inclusion and exclusion
riteria and participating sites are listed in the Online Appendix.
tudy procedures. Patients were randomly assigned 1:1 to
rasugrel 10 mg or clopidogrel 75 mg daily for 7 days.
atients returned over the course of the washout period for
latelet function assessment (Fig. 1). Randomization and
isit details are provided in the Online Appendix. Patients
ere considered to have completed the study when plateletunction returned to baseline according to the primary and
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end of the 12-day washout pe-
riod if platelet function did not
return to baseline.
Platelet function measurement.
Platelet function was assessed by
using the VerifyNow P2Y12 test
(Accumetrics, San Diego, Cali-
fornia), which measures adeno-
sine diphosphate–induced plate-
let aggregation as an increase in
light transmittance and reports
values in PRU (7). A higher
PRU reflects greater platelet reactivity.
Genetic methodology. Genotyping for CYP2C19*2,*3,
and *17 was performed by using TaqMan assays. CYP2C19
metabolizer phenotype was categorized as either extensive
or reduced, as previously described (8).
Definitions and endpoints. The primary endpoint of the
rial was the return to baseline platelet function after study drug
iscontinuation. Return to baseline was defined as platelet
eactivity within 60 PRU of reactivity before study drug
dministration. This window is within 1 SD of baseline
eactivity measured by using the VerifyNow P2Y12 test in a
revious study of patients with stable CAD (7). Analyses were
lso performed with a secondary definition of return to base-
ine: inhibition of platelet aggregation (IPA), defined as:
(PRUpre-study drug – PRU)/(PRUpre-study drug)  100],
20%. High residual platelet reactivity was defined as230
PRU (9).
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
IPA  inhibition of platelet
aggregation
MD  maintenance dose
PRU  P2Y12 reaction
units
Figure 1 Trial Design
Patients were randomly assigned to either prasugrel 10 mg daily or clopidogrel 75
returned over the washout period for platelet function assessment. AE  adverse
VS  vital signs.The main objective was to describe the primary endpoint
over the washout period. Secondary objectives were to: 1) deter-
mine the day at which 50%, 75%, and 90% of patients
eturned to baseline platelet function; 2) determine the day at
hich the proportion of prasugrel-treated patients who had
eturned to baseline function was closest to the proportion of
lopidogrel-treated patients who had returned to baseline
unction at washout days 5 and 7; and 3) examine the
elationship between IPA 24 h after the last dose of study drug
nd the number of days required to return to baseline function.
tatistical analysis. The analysis population was defined as
ll patients who had completed the study drug phase and had
latelet function data available at baseline and 24 h after study
rug discontinuation. The safety population was defined as all
atients who received at least 1 dose of study drug. Kaplan-
eier analysis was used to estimate the proportion of patients
ho returned to baseline platelet function over time. Multi-
ariate regression of the pooled treatment groups was per-
ormed to determine variables independently associated with
he primary endpoint. Details of this analysis and the sample
ize calculation are described in the Online Appendix.
esults
tudy flow is shown in Figure 2. A total of 56 patients were
andomized and received at least 1 dose of study drug; 54 were
ncluded in the analysis population, and 53 completed the
tudy visits. Patient demographic and clinical characteristics, as
ell as concomitant medication use, are shown in Table 1.
ily for 7 days, at which time study drug was discontinued. Patients then
PE  physical examination; PFT  platelet function test; V  visit;mg da
event;
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June 19/26, 2012:2338–43 Recovery of Platelet Function After Prasugrel/ClopidogrelPlatelet function over time. Pre-treatment platelet reactivity
was 285  46 PRU and 298  47 PRU among the patients
randomly assigned to receive prasugrel and clopidogrel,
respectively. Residual platelet reactivity was lower 24 hours
after the last dose of prasugrel compared with clopidogrel
(78 36 PRU vs. 196 81 PRU); IPA was 72 12% after
rasugrel administration compared with 35  23% after
lopidogrel administration (Fig. 3). No patients assigned to
S
Ra
Prasugrel (n=29) 
Completed study 
(n=27) 
Withdrew (n=2) 
Adverse event (n=0) 
Protocol violation (n=1) 
Subject withdrew consent (n=1) 
Analysis population (n=
Figure 2 Study Flow
Fifty-six patients were randomized and received at least 1 dose of study drug, repr
phase and had, at a minimum, platelet function data before study drug administra
Baseline Characteristics of the Study PopulationTable 1 Baseline Characteristics of the Study Population
Characteristic
Prasugrel
(n  29)
Clopidogrel
(n  27)
Total
(N  56)
Age (yrs) 57.5 8.45 62.3 8.10 59.8 8.56
Male 25 (86.2) 20 (74.1) 45 (80.4)
Body mass index (kg/m2) 32.0 4.07 30.3 5.34 31.2 4.76
Current smoker* 6 (20.7) 5 (18.5) 11 (19.6)
Diabetes mellitus 11 (37.9) 11 (40.7) 22 (39.3)
Hypertension 22 (75.9) 17 (63.0) 39 (69.6)
Hyperlipidemia 28 (96.6) 26 (96.3) 54 (96.4)
CYP2C19 phenotype
Extensive metabolizer 25 (86.2) 23 (85.2) 48 (85.7)
Reduced metabolizer 4 (13.8) 3 (11.1) 7 (12.5)
Unavailable 0 (0) 1 (3.7) 1 (1.8)
Prior medication use
Aspirin 29 (100) 27 (100) 56 (100)
Aspirin 81 mg daily 23 (79.3) 18 (66.7) 44 (73.2)
Proton pump inhibitors 3 (10.3) 1 (3.7) 4 (7.1)
Dihydropyridine calcium-
channel blocker
4 (13.8) 3 (11.1) 7 (12.5)
Non-dihydropyridine
calcium-channel blocker
0 (0) 1 (3.7) 1 (1.8)
Beta-blocker 15 (51.7) 14 (51.9) 29 (51.8)
HMG-CoA reductase inhibitor 25 (86.2) 20 (74.1) 45 (80.4)
ACE inhibitor 14 (48.3) 12 (44.4) 26 (46.4)
Values are mean  SD or n (%). *Current smoker 10 cigarettes per day.
ACE  angiotensin-converting enzyme; CYP  cytochrome P450; HMG-CoA  3-hydroxy-3-
ethylglutaryl-coenzyme A.rasugrel and 11 patients (42%) assigned to clopidogrel
isplayed high residual platelet reactivity.
Figure 4 shows the cumulative proportion of patients
eturning to baseline platelet reactivity over the washout
eriod. In the prasugrel group, 50% of patients returned
o baseline reactivity by washout day 6, 75% by day 7, and
90% by day 9; in the clopidogrel group, 50% of patients
ed (n=70) 
ized (n=56) 
Clopidogrel (n=27) 
Completed study 
(n=26) 
Withdrew (n=1) 
Adverse event (n=1) 
Analysis population (n=26) 
ng the safety population. Fifty-four patients completed the study drug
nd at 24 hours after discontinuation, representing the analysis population.
Figure 3 Residual Platelet Reactivity Over Time by
Individual Patient and Study Group Assignment
The initial magnitude of platelet inhibition at discontinuation was an indepen-
dent predictor of the time to recovery, resulting, on average, in a more pro-
longed recovery after prasugrel. PRU  P2Y12 reaction units.creen
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Recovery of Platelet Function After Prasugrel/Clopidogrel June 19/26, 2012:2338–43returned to baseline reactivity by washout day 3,75% by day
5, and 90% by day 6. Washout day 7 was the day at which
he proportion of prasugrel-treated patients who had returned
o baseline reactivity was closest to the proportion attained by
he clopidogrel-treated group at washout day 5 (22 [78%] vs.
2 patients [85%], respectively). Similar findings were observed
sing the definition of return to baseline as20% IPA, except
90% of patients in the clopidogrel group had recovered by
washout day 7 rather than day 6.
Predictors of recovery time. According to multivariate analysis,
the level of platelet reactivity before study drug exposure and the
IPA 24 h after study drug discontinuation were independently
associated with the number of days to the return to baseline
platelet function (p  0.0001 for both; adjusted R2 for final
odel  0.72). Treatment assignment was not associated
Figure 4 Cumulative Proportion of Patients Returning to
Baseline Reactivity After Thienopyridine Discontinuation
(A) Baseline platelet reactivity defined as within 60 PRU of the reactivity mea-
sured before study drug exposure and (B) baseline platelet function defined as
inhibition of platelet aggregation 20%. PRU  P2Y12 reaction units.with recovery time after adjusting for these variables.Safety. Ten patients in the prasugrel group and 5 in the
clopidogrel group experienced treatment-emergent adverse
events; none was serious. The adverse events were consid-
ered study drug–related in 4 prasugrel-treated patients and
2 clopidogrel-treated patients (Table 2). No bleeding events
were reported although 2 prasugrel-treated patients experienced
an increased tendency to bruise. One clopidogrel-treated patient
and no prasugrel-treated patients discontinued study drug due to
an adverse event.
Discussion
Surgical bleeding is significantly increased during and after
thienopyridine therapy. These observations, together with the
irreversible antagonism of the platelet P2Y12 receptor provided
y these agents, has led to empirical recommendations for the
ptimal waiting period for surgery after thienopyridine discon-
inuation (6). In this study, we found that in aspirin-treated
atients with CAD, the time to platelet functional recovery
fter thienopyridine MD depended on the level of platelet
eactivity before study drug exposure and the initial magnitude of
latelet inhibition after discontinuation. Therefore, the greater
ntiplatelet effect of prasugrel resulted, on average, in a more
elayed recovery of platelet function compared with clopidogrel.
urthermore, we observed that a waiting period of 7 days after
rasugrel cessation provided a degree of recovery closest to the
-day waiting period for clopidogrel, at which point the antiplate-
et effects of both agents had dissipated in75% of patients. Our
ndings are consistent with, and provide pharmacodynamic sup-
ort for, current guidelines regarding the recommended waiting
ime for surgery after prasugrel discontinuation (6).
Rates of major bleeding, blood transfusions, reoperation,
nd lengths of stay are increased among patients undergoing
ABG 5 days of last exposure to clopidogrel (3,4). Among
atients who underwent CABG in the TRITON-TIMI 38
rial, the rate of CABG-related bleeding was significantly
reater with prasugrel compared with clopidogrel, and this
ncreased risk persisted up to 7 days from the most recent dose
f study drug (5). We observed that most clopidogrel-treated
atients recovered platelet function by 5 days after drug
essation, and the proportion of prasugrel-treated patients who
ecovered platelet function was most similar to this time point
t 7 days after cessation. The lack of an increased bleeding risk
n clinical studies after a 5- and 7-day waiting period with
lopidogrel and prasugrel, respectively, is consistent with our
Subjects With Drug-Related Treatment-Emergent Adverse Ev nts in the Safety Population*Table 2 Subj cts Wi h Drug-Related Treatme t-Emergent Adverse Events in the Safety Population*
Adverse Event
Prasugrel
(n  29)
Clopidogrel
(n  27)
Ecchymosis 0 1
Increased tendency to bruise 2 0
Epistaxis 2 0
Diarrhea 1 1
Diabetes mellitus 0 1
Insomnia 0 1*Subjects may have experienced 1 or more event.
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June 19/26, 2012:2338–43 Recovery of Platelet Function After Prasugrel/Clopidogrelpharmacodynamic findings. Although most patients in the
current study returned to baseline platelet reactivity after 5 and
7 days of clopidogrel and prasugrel discontinuation, respec-
tively, patients in both groups displayed residual effects beyond
these waiting periods. Because lower levels of adenosine
diphosphate–induced platelet reactivity are associated with
increased surgical bleeding (10), a longer waiting period (6 to
7 days for clopidogrel and 9 days for prasugrel) could be
desirable to further mitigate any potential bleeding risk due
to thienopyridine-induced platelet inhibition.
Our findings highlight the interindividual variability in the
recovery time after clopidogrel exposure that is a direct conse-
quence of clopidogrel response variability (9). In the current study,
87% of the patients randomly assigned to clopidogrel had fully
recovered platelet function after the guideline-recommended
5-day waiting period. However, because the inhibitory response to
clopidogrel was substantially variable, and functional recovery time
was dependent on the initial magnitude of platelet inhibition,
one-half of the clopidogrel-treated patients recovered platelet
function by day 3 while several had persistent inhibition beyond 5
days. This observation is consistent with previous studies of
platelet functional recovery after clopidogrel treatment (11). A
uniform strategy of a 5-day waiting period after clopidogrel could
expose patients with marginal response to thrombotic risk, while
exposing “hyper-responders” to an increased surgical bleeding risk.
Platelet function testing could help guide surgical timing in
thienopyridine-treated patients to minimize bleeding complica-
tions, although the evidence supporting such an approach is
limited by the lack of firm cutoffs to predict bleeding events.
Study limitations. We could not determine the mean levels
of platelet reactivity or inhibition for the entire study popula-
tion after the first washout visit because we did not collect
platelet function data after subjects’ platelet reactivity returned
to baseline according to the protocol definition. We assessed
platelet function solely by using the VerifyNow P2Y12 test.
The small sample size may have limited our ability to detect the
influence of CYP2C19 and other clinical variables. We did not
assess clinical outcomes post-surgery and therefore could not
directly correlate pharmacodynamics with surgical bleeding.
The distribution of aspirin dose differed by chance between
treatment groups; however, the consistent aspirin exposure for
each patient throughout the course of the study diminished the
likelihood of this imbalance affecting the study findings.
Conclusions
In aspirin-treated patients with stable CAD, the antiplatelet
effects of prasugrel 10 mg MD were greater than those of
clopidogrel 75 mg MD. After discontinuation, the propor-
tion of patients who recovered platelet function on day 5 of
clopidogrel was similar to day 7 of prasugrel. The initialindependent predictor of the time to recovery, resulting, on
average, in a more prolonged recovery after prasugrel. Our
findings are consistent with current guidelines and product
labeling regarding the recommended waiting time for sur-
gery after discontinuation of prasugrel.
Acknowledgment
The authors thank Maggie Markiewicz, Clinical Study
Manager, for ensuring data integrity through oversight and
management of this study.
Reprint requests and correspondence: Dr. Matthew J. Price,
Division of Cardiovascular Diseases, Scripps Clinic, 10666 North
Torrey Pines Road, Maildrop S1056, La Jolla, California 92037.
E-mail: price.matthew@scrippshealth.org.
REFERENCES
1. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel
and clopidogrel loading doses on platelet function: magnitude of
platelet inhibition is related to active metabolite formation. Am
Heart J 2007;153:66.e9–16.
2. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater
inhibition of platelet aggregation and a lower rate of non-responders
compared with clopidogrel in aspirin-treated patients with stable
coronary artery disease. Eur Heart J 2006;27:1166–73.
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of
clopidogrel in addition to aspirin in patients with acute coronary syndromes
without ST-segment elevation. N Engl J Med 2001;345:494–502.
4. Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker
RC. Impact of clopidogrel in patients with acute coronary syndromes
requiring coronary artery bypass surgery: a multicenter analysis. J Am
Coll Cardiol 2008;52:1693–701.
5. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel
in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15.
6. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA
focused update of the guidelines for the management of patients with
unstable angina/non-ST-elevation myocardial infarction (updating the
2007 guideline): a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines. Circulation 2011;123:2022–60.
7. Varenhorst C, James S, Erlinge D, et al. Assessment of P2Y12 inhibition with
the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel
or clopidogrel coadministered with aspirin. Am Heart J 2009;0:1.e1–1.e9.
8. Varenhorst C, James S, Erlinge D, et al. Genetic variation of
CYP2C19 affects both pharmacokinetic and pharmacodynamic re-
sponses to clopidogrel but not prasugrel in aspirin-treated patients
with coronary artery disease. Eur Heart J 2009;30:1744–52.
9. Bonello L, Tantry US, Marcucci R, et al. Consensus and future
directions on the definition of high on-treatment platelet reactivity to
adenosine diphosphate. J Am Coll Cardiol 2010;56:919–33.
10. Ferreiro JL, Sibbing D, Angiolillo DJ. Platelet function testing and
risk of bleeding complications. Thromb Haemost 2010;103:1128–35.
11. Price MJ, Teirstein PS. Dynamics of platelet functional recovery
following a clopidogrel loading dose in healthy volunteers. Am J
Cardiol 2008;102:790–5.
Key Words: bleeding y clopidogrel y platelet function y prasugrel y
surgery y thienopyridine.
APPENDIX
For supplementary details regarding the study protocol,
magnitude of platelet inhibition at discontinuation was an please see the online version of this article.
Go to http://cme.jaccjournals.org
to take the CME quiz for this article.
